Dusseldorf - Delayed Quote EUR

BioNTech SE (22UA.DU)

118.50

+0.50

+(0.42%)

At close: January 31 at 7:31:17 PM GMT+1

Moderna Yo-Yos After European Officials Ink Supply Deal For Covid Shots

Moderna won an agreement for its Covid vaccines in Europe on Friday, but Moderna stock reversed its early gains.

Investor's Business Daily 7 days ago

BNTX

PFE

NVAX
3 Dirt-Cheap Stocks to Buy in a Market That's Priced for Perfection

How expensive is the stock market right now? BioNTech (NASDAQ: BNTX) vaulted into the spotlight in 2020 when Pfizer teamed up with the then-small German company to develop a COVID-19 vaccine. Today, BioNTech is much larger with a market cap of around $27 billion.

Motley Fool 10 days ago

BNTX

^GSPC

ET
Wall Street Analysts Predict a 25.59% Upside in BioNTech (BNTX): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 25.6% in BioNTech (BNTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks 14 days ago

BNTX
BioNTech Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference

Executing in oncology with investigational BNT327/PM8002 combinations and mRNA cancer immunotherapy candidates as pan-tumor treatment approaches BioNTech aims to develop BNT327/PM8002 as a next-generation immuno-oncology (“IO”) backbone for the Company’s combination strategy targeting a broad range of indicationsProgressing development of BNT327/PM8002 with initiation of global clinical trials with registrational potential in first-line small cell lung cancer (“SCLC”) and non-small cell lung can

GlobeNewswire 18 days ago

BNTX
BioNTech Positioned For Solid Growth Amid Oncology Transition: Analyst

On Thursday, Truist initiated coverage on BioNTech SE (NASDAQ:BNTX), a famed COVID-19 vaccine maker, in collaboration with Pfizer Inc (NYSE:PFE). BioNTech is transitioning from a COVID-focused narrative to a story centered on oncology drug development and upcoming catalysts. The analyst, Asthika Goonewardene, writes that BNT327 is at the forefront, a promising drug in an innovative class that could challenge and potentially surpass the PD-1 category, which generated over $42 billion in 2023. Als

Benzinga 21 days ago

BNTX
Moderna, BioNTech, Novavax Surge After CDC Reports Two-Week Covid Spike

Moderna stock surged Tuesday after the Centers for Disease Control and Prevention noted a two-week spike in positive Covid tests.

Investor's Business Daily 24 days ago

MRNA

BNTX

NVAX
Private equity firms who hold 43% of BioNTech SE (NASDAQ:BNTX) gained 6.8%, institutions profited as well

Key Insights Significant control over BioNTech by private equity firms implies that the general public has more power...

Simply Wall St. 24 days ago

BNTX
Drug-Trial Results Could Shake Up Pharma Stocks in 2025. Watch Eli Lilly, Pfizer, and More.

For pharmaceutical stocks, there are few events as crucial as the results of clinical trials for new drugs.

Barrons.com last month

LLY

PFE

NVO
NIH settlement ‘manageable headwind’ for BioNTech, Pfizer, says Morgan Stanley

Morgan Stanley analyst Terence Flynn notes that BioNTech (BNTX) announced last week that it had reached a settlement agreement with the National Institutes of Health and University of Pennsylvania regarding past and future royalties on the company and partner Pfizer’s (PFE) COVID vaccine, Comirnaty. Noting that the deal will result in two low-single digit percentage royalties on forward sales of Comirnaty and the companies will pay $1.15B for historical royalties, the firm says it views this as

TipRanks last month

PFE

BNTX
BioNTech to pay $467M in settlement agreement with University of Pennsylvania

In a regulatory filing, BioNTech (BNTX) said, “BioNTech previously disclosed that it was in discussions with the University of Pennsylvania concerning royalties and other related amounts allegedly owed on sales of the Company’s, and its collaboration partner, Pfizer’s (PFE) COVID-19 vaccine since commercialization. On December 23, 2024, the Company entered into a binding term sheet with Penn to provide terms on which the Company retains license rights under certain Penn patent rights in order to

TipRanks last month

BNTX

PFE
BioNTech to pay $791.5M in settlement agreement with the NIH

In a regulatory filing, BioNTech (BNTX) said, “BioNTech previously disclosed that it was in discussions with the National Institutes of Health concerning royalties and other related amounts allegedly owed on sales of the Company’s, and its collaboration partner, Pfizer’s (PFE) COVID-19 vaccine since commercialization. On December 20, 2024, the Company entered into a settlement agreement with the NIH. Under the terms of the Settlement Agreement, the Company will, among other things, pay $791.5M,

TipRanks last month

BNTX

PFE
BioNTech Settles Royalty Dispute with NIH for $791.5 Million

BioNTech SE ( (BNTX) ) has provided an update. BioNTech SE has settled a dispute with the National Institutes of Health (NIH) regarding royalties allegedly owed on sales of its COVID-19 vaccine, developed in collaboration with Pfizer. The settlement involves a payment of $791.5 million to the NIH, resolving past claims and adjusting future royalty arrangements. The settlement does not imply any admission of liability by BioNTech, and Pfizer has agreed to reimburse $364.5 million of the settlemen

TipRanks last month

BNTX
BioNTech Settles Royalty Dispute with University of Pennsylvania

The latest update is out from BioNTech SE ( (BNTX) ). BioNTech SE has reached a settlement agreement with the University of Pennsylvania over a royalty dispute related to its COVID-19 vaccine, developed in collaboration with Pfizer. The agreement involves a payment of up to $467 million to Penn, which includes royalties for past sales and funding for extended research collaboration. Pfizer has also agreed to reimburse BioNTech for part of these royalties. More about BioNTech SE BioNTech SE is a

TipRanks last month

BNTX
BioNTech Announces Settlement With National Institutes of Health, University of Pennsylvania Over Royalty Claims

BioNTech (BNTX) on Friday announced separate agreements with the US National Institutes of Health an

PREMIUM
MT Newswires last month

BNTX

PFE
Top Midday Stories: UnitedHealth, Amedisys Extend Deal-Close Deadline; OpenAI Mulling a For-Profit Structure

All three major US stock indexes were down more than 1% in late-morning trading Friday, as the marke

PREMIUM
MT Newswires last month

AMED

UNH

MSFT
BioNTech's Big Moves: $1.2 Billion Settlements and a Game-Changing Cancer Bet

Settling royalty disputes and acquiring Biotheus, BioNTech reshapes its future in vaccines and oncology innovation.

GuruFocus.com last month

BNTX
BioNTech enters settlement with US agency, UPenn over COVID vaccine royalties

The German company, which partners with U.S. drugmaker Pfizer for its COVID-19 vaccine, said on Friday it would pay $791.5 million to the U.S. agency to resolve a default notice. Separately, the company will pay $467 million to the University of Pennsylvania (Penn), which has agreed to dismiss a lawsuit brought against the vaccine maker accusing it of underpaying royalties.

Reuters last month

BNTX

PFE
2 Reasons to Sell Merck Stock and 1 Reason to Buy

There is plenty to like about Merck (NYSE: MRK). It is one of the largest pharmaceutical companies and the owner of the world's current best-selling drug, cancer medicine Keytruda. Merck generates consistent revenue and profits, has a deep pipeline, and pays a regular dividend.

Motley Fool last month

BNTX
3 No-Brainer Biotech Stocks to Buy With $200 Right Now

Here are three no-brainer biotech stocks to buy with $200 right now. Biotech stocks usually appeal more to aggressive growth investors, while value investors typically prefer to look elsewhere. You can scoop up a share of BioNTech for less than $120 at the time of this writing.

Motley Fool last month

BNTX

MRNA

SMMT
2 Healthcare Stocks to Buy Hand Over Fist and 1 to Avoid

Here are two healthcare stocks to buy hand over fist and one to avoid. In the third quarter of 2021, BioNTech (NASDAQ: BNTX) raked in revenue of over 6 billion euros (around $6.9 billion based on the then-current exchange rate). Fast forward to Q3 of 2024, and BioNTech's revenue was only 1.24 billion euros (roughly $1.3 billion), due to the steep decline in demand for the COVID-19 vaccine the company markets with its partner Pfizer.

Motley Fool last month

TMDX

BNTX

WBA

Performance Overview

Return	22UA.DU	MSCI WORLD
YTD	+9.52%	+3.16%
1-Year	+34.05%	+19.69%
3-Year	-21.25%	+25.42%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

BioNTech SE (22UA.DU)

Moderna Yo-Yos After European Officials Ink Supply Deal For Covid Shots

3 Dirt-Cheap Stocks to Buy in a Market That's Priced for Perfection

Wall Street Analysts Predict a 25.59% Upside in BioNTech (BNTX): Here's What You Should Know

BioNTech Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference

BioNTech Positioned For Solid Growth Amid Oncology Transition: Analyst

Moderna, BioNTech, Novavax Surge After CDC Reports Two-Week Covid Spike

Private equity firms who hold 43% of BioNTech SE (NASDAQ:BNTX) gained 6.8%, institutions profited as well

Drug-Trial Results Could Shake Up Pharma Stocks in 2025. Watch Eli Lilly, Pfizer, and More.

NIH settlement ‘manageable headwind’ for BioNTech, Pfizer, says Morgan Stanley

BioNTech to pay $467M in settlement agreement with University of Pennsylvania

BioNTech to pay $791.5M in settlement agreement with the NIH

BioNTech Settles Royalty Dispute with NIH for $791.5 Million

BioNTech Settles Royalty Dispute with University of Pennsylvania

BioNTech Announces Settlement With National Institutes of Health, University of Pennsylvania Over Royalty Claims

Top Midday Stories: UnitedHealth, Amedisys Extend Deal-Close Deadline; OpenAI Mulling a For-Profit Structure

BioNTech's Big Moves: $1.2 Billion Settlements and a Game-Changing Cancer Bet

BioNTech enters settlement with US agency, UPenn over COVID vaccine royalties

2 Reasons to Sell Merck Stock and 1 Reason to Buy

3 No-Brainer Biotech Stocks to Buy With $200 Right Now

2 Healthcare Stocks to Buy Hand Over Fist and 1 to Avoid

Performance Overview